FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

3...,

OMB APPROVAL								
OMB Number:	3235-028							

OMB Number: 3235-0287 Estimated average burden hours per response: 0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

1. Name and Address of Reporting Person* <u>Heffernan Michael Thomas</u>					<u>CC</u>	2. Issuer Name and Ticker or Trading Symbol COLLEGIUM PHARMACEUTICAL, INC COLL									ationship k all appli Directo	cable)	ıg Per	son(s) to Iss 10% Ov	
	LLEGIUM	rst) (PHARMACEUT		IC.	04/	3. Date of Earliest Transaction (Month/Day/Year) 04/25/2019												Other (s	
(Street) STOUGI			02072		_ 4. If	4. If Amendment, Date of Original Filed (Month/Day/Year)								i. Individual or Joint/Group Filing (Check Applicable line) X Form filed by One Reporting Person Form filed by More than One Reporting Person					
(City)	(S		(Zip)																
		Tab	le I - Nor	ı-Deriv	ative	Sec	curitie	s Ac	quired,	Disp	osed o	of, or Be	enefic	ally	Owned	l			
1. Title of Security (Instr. 3) 2. Transac Date (Month/Da					ay/Year) if		2A. Deemed Execution Date, if any (Month/Day/Year)		Code (Instr.		4. Securities Acquired (A) Disposed Of (D) (Instr. 3, 5)			5. Amou Securitie Benefici Owned F Reporte	es ally Following	Form (D) o	: Direct r Indirect str. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)	
										v	Amount	(A) (D)	Pric	е	Transaci (Instr. 3	tion(s)			(111511.4)
Common Stock 04/25/				5/2019	2019			A		4,707	707 ⁽¹⁾ A		0	207,069			D		
	Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)																		
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deeme Execution if any (Month/Day	Date,	ate, Transa Code (I		5. Num of Deriva Securi Acquir (A) or Dispos of (D) (Instr.: and 5)	tive ties ed	Expiration	Date Exercisable and piration Date lonth/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		D S (I	Price of erivative ecurity nstr. 5)	9. Number derivative Securities Beneficial Owned Following Reported Transactio (Instr. 4)	i lly	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	Beneficial Ownership ct (Instr. 4)
				Co	Code	v	(A)	(D)	Date Exercisable		xpiration ate	Title	Amount or Number of Shares	er					
Stock Option (Right to	\$14.57	04/25/2019			A		9,414		(2)	04	4/25/2029	Common Stock	9,41	4	\$0	9,414		D	

Explanation of Responses:

1. Reflects the grant of restricted stock units. Each restricted stock unit represents a contingent right to receive one share of the issuer's common stock. The restricted stock units vest on April 25, 2020, subject to the director's continued service with the issuer. The restricted stock units will be settled on such date, or, upon the election of the director, on the earlier of the end of the director's service on the Board of Directors, the director's death or disability, or a change in control of the issuer, in shares of the issuer's common stock.

Remarks:

/s/ Paul Brannelly as Attorney-

In-Fact For Michael T. 04/29/2019

Heffernan

** Signature of Reporting Person Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

- * If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

^{2.} The option vests and becomes exercisable on April 25, 2020, subject to the director's continued service with the issuer